November 2018 Pharmaceutical Schedule Dispatch

This document is provided to pharmacists as an early notification of the changes to be announced in the November 2018 Update to the Pharmaceutical Schedule. Please notify PHARMAC (enquiry@pharmac.govt.nz) if you want to change or remove your contact details.

New listings

- Amino acid formula (Neocate SYN EO) powder (unflavoured), 400 g OP – Special Authority – Hospital pharmacy [HP3] (p’code 2555271)
- Cholestyramine (Questran-Lite S29) powder for oral liq 4 g – S29 and wastage claimable (p’code 2555883)
- Clarithromycin (Klacid) granules for oral liq 250 mg per 5 ml, 50 ml – wastage claimable – maximum of 500 mg per prescription; can be waived by Special Authority (p’code 2535378)
- Cyclizine hydrochloride (Nausic alm) tab 50 mg (p’code 2231220)
- Dorzolamide with timolol (Dortimopt) eye drops 2% with timolol 0.5%, 5 ml OP (p’code 2398354)
- Ergometrine maleate (Ergonovine) inj 250 mcg per ml, 1 ml ampoule – up to 5 inj available on a PSO, S29 and wastage claimable (2557061)
- Eformoterol fumarate dihydrate (Oxis Turbuhaler) powder for inhalation 4.5 mcg per dose, breath activated (equivalent to eformoterol fumarate 6 mcg metered dose), 60 dose OP (p’code 2554232)
- Hydrogen peroxide (Crystaderm) crm 1%, 10 g OP (p’code 2399504)
- Insulin pump min basal rate 0.001 U/h (Tandem t:slin X2) (p’code 2556928) and min basal rate 0.025 U/h (MiniMed 640G) (p’code 2556693) – Special Authority – Retail pharmacy – maximum of 1 dev per prescription, only on a prescription and maximum of 1 insulin pump per patient each four year period
- Insulin pump infusion set (steel cannula, straight insertion) (TruSteel) 6 mm steel cannula; straight insertion; 60 cm line x 10 with 10 needles (p’code 2556863); 6 mm steel cannula; straight insertion; 81 cm line x 10 with 10 needles (p’code 2556871); 8 mm steel cannula; straight insertion; 60 cm line x 10 with 10 needles (p’code 2556898) and 8 mm steel cannula; straight insertion; 81 cm line x 10 with 10 needles (p’code 2556901), 1 OP – Special Authority – Retail pharmacy – maximum of 3 sets per prescription, only on a prescription and maximum of 12 infusion sets will be funded per year
- Insulin pump infusion set (teflon cannula, angle insertion with insertion device) (Autosoft 30) 13 mm teflon cannula; angle insertion; insertion device; 60 cm line x 10 with 10 needles (p’code 2556847) and 13 mm teflon cannula; angle insertion; insertion device; 110 cm line x 10 with 10 needles (p’code 2556855), 1 OP – Special Authority –
Retail pharmacy – maximum of 3 sets per prescription, only on a prescription and maximum of 12 infusion sets will be funded per year

- Insulin pump infusion set (teflon cannula, straight insertion with insertion device) (Autosoft 90) 6 mm teflon cannula; straight insertion; insertion device; 60 cm line x 10 with 10 needles (p’code 2556804); 6 mm teflon cannula; straight insertion; insertion device; 110 cm line x 10 with 10 needles (p’code 2556812); 9 mm teflon cannula; straight insertion; insertion device; 60 cm line x 10 with 10 needles (p’code 2556820) and 9 mm teflon cannula; straight insertion; insertion device; 110 cm line x 10 with 10 needles (p’code 2556839), 1 OP – Special Authority – Retail pharmacy – maximum of 3 sets per prescription, only on a prescription and maximum of 12 infusion sets will be funded per year

- Insulin pump cartridge (Tandem Cartridge) cartridge 300 U, t:lock x 10, 1 OP – Special Authority – Retail pharmacy – Maximum of 3 sets per prescription, only on a prescription and maximum of 13 packs of cartridge sets will be funded per year (p’code 2556790)

- Methotrexate (Trexate) tab 2.5 mg (p’code 2537060) and 10 mg (p’code 2537079), 90 tab pack – PCT – Retail pharmacy-Specialist

- Pancreatic enzyme (Creon 25000) cap pancreatin 300 mg (amylase 18,000 Ph Eur U, lipase 25,000 Ph Eur U, total protease 1,000 Ph Eur U) (p’code 2535319)

- Paraffin (healthE) oint liquid paraffin 50% with white soft paraffin 50%, 500 ml OP (p’code 2322072)

- Pharmacy services (BSF Apo-Gabapentin (p’code 2556626), BSF Aripiprazole Sandoz (p’code 2556634) and BSF Tenofovir Disoproxil Teva (p’code 2556642)) brand switch fee – may only be claimed once per patient

- Primidone (Mysoline S29) tab 250 mg – S29 and wastage claimable (p’code 2557053)

- Povidone iodine (Orion) skin preparation, povidone iodine 10% with 70% alcohol, 100 ml (p’code 2556286)

- Sapropterin dihydrochloride (Kuvan) tab soluble 100 mg, 30 tab OP – Special Authority – Retail pharmacy (p’code 2351676)

- Tamoxifen citrate (Tamoxifen Sandoz) tab 10 mg (p’code 2556944) and 20 mg (p’code 2556952)

Changes to restrictions, chemical names and presentations

- Aripiprazole (Aripiprazole Sandoz) tab 5 mg, 10 mg, 15 mg, 20 mg and 30 mg – addition of Brand Switch Fee

- Gabapentin (Apo-Gabapentin) cap 100 mg, 300 mg and 400 mg – addition of Brand Switch Fee

- Glyceryl trinitrate (Glytrin) oral spray, 400 mcg per dose, 200 dose OP – amended PSO quantity

- Medroxyprogesterone acetate (Provera) tab 2.5 mg – stat dispensing reinstated
- Phenytoin sodium (Dilantin) oral liq 30 mg per 5 ml – stat dispensing removed
- Tenofovir disoproxil (Tenofovir Disoproxil Teva) tab 245 mg (300.6 mg as a succinate)
  – addition of Brand Switch Fee

### Increased subsidy

<table>
<thead>
<tr>
<th>Chemical</th>
<th>Presentation</th>
<th>Fully subsidised brands</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doxorubicin hydrochloride</td>
<td>Inj 2 mg per ml, 100 ml vial</td>
<td>Doxorubicin Ebewe</td>
</tr>
<tr>
<td>Ferrous fumarate</td>
<td>Tab 200 mg (65 mg elemental)</td>
<td>Ferro-tab</td>
</tr>
<tr>
<td>Oxaliplatin</td>
<td>Inj 5 mg per ml, 20 ml vial</td>
<td>Oxaliceord</td>
</tr>
</tbody>
</table>

### Decreased subsidy

<table>
<thead>
<tr>
<th>Chemical [lignocaine] hydrochloride</th>
<th>Presentation</th>
<th>Fully subsidised brands</th>
<th>Partially subsidised brands</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calamine</td>
<td>Crm, aqueous, BP, 100 g</td>
<td>healthE Calamine Aqueous Cream BP*</td>
<td>Pharmacy Health</td>
</tr>
<tr>
<td>Colchicine</td>
<td>Tab 500 mcg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heparin sodium</td>
<td>Inj 1,000 iu per ml, 35 ml vial</td>
<td>Hospira</td>
<td></td>
</tr>
<tr>
<td>Heparin sodium</td>
<td>Inj 1,000 iu per ml, 5 ml ampoule, 10 and 50 inj pack</td>
<td>Pfizer*</td>
<td>Hospira</td>
</tr>
<tr>
<td>Lidocaine [lignocaine] hydrochloride</td>
<td>Inj 2%, 5 ml ampoule</td>
<td>Lidocaine-Claris</td>
<td></td>
</tr>
<tr>
<td>Losartan potassium with hydrochlorothiazide</td>
<td>Tab 50 mg with hydrochlorothiazide 12.5 mg</td>
<td>Arrow-Losartan &amp; Hydrochlorothiazide</td>
<td></td>
</tr>
<tr>
<td>Oil in water emulsion</td>
<td>Crm, 500 g</td>
<td>O/W Fatty Emulsion Cream</td>
<td></td>
</tr>
<tr>
<td>Thiamine hydrochloride</td>
<td>Tab 50 mg</td>
<td>Max Health*</td>
<td>Apo-Thiamine</td>
</tr>
</tbody>
</table>

* no subsidy changes for these brands for 1 November 2018.